ArticleCancer management and research2017

APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial.

Ian D Schnadig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.